Is the Use of Proton Pump Inhibitors a Predisposing Factor for Pyogenic Liver Abscesses?
Infection
Liver abscess
Proton pump inhibitors
Journal
Gastroenterology research
ISSN: 1918-2805
Titre abrégé: Gastroenterology Res
Pays: Canada
ID NLM: 101519422
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
28
04
2021
accepted:
02
06
2021
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) increase gastric pH by reducing acid production. The resulting alkaline milieu in the stomach increases the risk of bacterial translocation. This study aimed to investigate if there is a correlation between PPI use and developing pyogenic liver abscesses. In this retrospective case-control analysis, we studied adult patients diagnosed with cryptogenic liver abscess at Northwell hospitals between 2015 and 2019. Adult patients with the diagnosis of liver abscess were included. We excluded patients with history of liver abscess prior to admission, biliary disease, hepatobiliary malignancy, or intra-abdominal infections. A group of randomly selected patients without liver abscess from the same hospitals' database were enrolled as the control group. A multivariate logistic regression analysis was performed to adjust for potential confounding factors. We identified 277 patients diagnosed with first episode of pyogenic liver abscess. Cases were compared to 554 controls. This study is the first US population-based analysis to demonstrate that PPI use is associated with increased risk of developing pyogenic liver abscesses. Further prospective studies are needed to shed more light on this association and better evaluate the impact of dose and duration of PPI exposure.
Sections du résumé
BACKGROUND
BACKGROUND
Proton pump inhibitors (PPIs) increase gastric pH by reducing acid production. The resulting alkaline milieu in the stomach increases the risk of bacterial translocation. This study aimed to investigate if there is a correlation between PPI use and developing pyogenic liver abscesses.
METHODS
METHODS
In this retrospective case-control analysis, we studied adult patients diagnosed with cryptogenic liver abscess at Northwell hospitals between 2015 and 2019. Adult patients with the diagnosis of liver abscess were included. We excluded patients with history of liver abscess prior to admission, biliary disease, hepatobiliary malignancy, or intra-abdominal infections. A group of randomly selected patients without liver abscess from the same hospitals' database were enrolled as the control group. A multivariate logistic regression analysis was performed to adjust for potential confounding factors.
RESULTS
RESULTS
We identified 277 patients diagnosed with first episode of pyogenic liver abscess. Cases were compared to 554 controls.
CONCLUSION
CONCLUSIONS
This study is the first US population-based analysis to demonstrate that PPI use is associated with increased risk of developing pyogenic liver abscesses. Further prospective studies are needed to shed more light on this association and better evaluate the impact of dose and duration of PPI exposure.
Identifiants
pubmed: 34267834
doi: 10.14740/gr1404
pmc: PMC8256900
doi:
Types de publication
Journal Article
Langues
eng
Pagination
184-189Informations de copyright
Copyright 2021, Elfiky et al.
Déclaration de conflit d'intérêts
No competing interests.
Références
Clin Gastroenterol Hepatol. 2013 May;11(5):483-90
pubmed: 23270866
Eur J Clin Pharmacol. 2017 Aug;73(8):1019-1025
pubmed: 28434021
Int J Environ Res Public Health. 2020 Nov 09;17(21):
pubmed: 33182362
Ann Surg. 1996 May;223(5):600-7; discussion 607-9
pubmed: 8651751
Expert Opin Drug Saf. 2020 Mar;19(3):327-334
pubmed: 31928106
Am J Gastroenterol. 2012 Jul;107(7):1011-9
pubmed: 22525304
Travel Med Infect Dis. 2008 Jul;6(4):228-33
pubmed: 18571114
Hepatology. 2016 Oct;64(4):1265-72
pubmed: 27474889
Aliment Pharmacol Ther. 2015 Jun;41(11):1175-81
pubmed: 25871643
JAMA Pediatr. 2021 Apr 1;175(4):394-403
pubmed: 33555324
Am J Gastroenterol. 2007 Sep;102(9):2047-56; quiz 2057
pubmed: 17509031
Am J Gastroenterol. 2010 Jan;105(1):117-24
pubmed: 19888200
Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):481-6
pubmed: 21739348
PLoS One. 2015 Jun 04;10(6):e0128004
pubmed: 26042842
Antimicrob Agents Chemother. 2006 Nov;50(11):3905-7
pubmed: 16940078
Crit Care Med. 2002 May;30(5):1118-22
pubmed: 12006811
Emerg Infect Dis. 2008 Oct;14(10):1592-600
pubmed: 18826824
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):235-246
pubmed: 30643227
Asia Pac J Clin Oncol. 2013 Jun;9(2):192-3
pubmed: 23298363
Aliment Pharmacol Ther. 2018 Mar;47(6):801-808
pubmed: 29327781
J Hosp Infect. 2018 Jan;98(1):4-13
pubmed: 28842261
Gen Pharmacol. 1995 Oct;26(6):1413-8
pubmed: 7590140